Novartis: Migraine Disorders trials
The registry lists 15 Migraine Disorders studies with Novartis as lead sponsor. 0 are open to participants now and 7 have results posted.
Phase 1 1Phase 2 2Phase 3 5Phase 4 4No phase 3(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label StudyCompletedNCT04084314Phase 4Results posted
- Study of Efficacy and Safety of Erenumab in Adult Chronic Migraine PatientsCompletedNCT03867201Phase 3Results posted
- Head-to-head Study of Erenumab Against Topiramate in Patients With Episodic and Chronic MigraineCompletedNCT03828539Phase 4Results posted
- Study of Efficacy and Safety of AMG 334 in Adult Episodic Migraine PatientsCompletedNCT03333109Phase 3Results posted
- A Study Evaluating the Effectiveness of AMG 334 Injection in Preventing Migraines in Adults Having Failed Other TherapiesCompletedNCT03096834Phase 3Results posted
- Efficacy and Safety of Acetaminophen and Aspirin Versus Placebo in the Acute Treatment of MigraineCompletedNCT01973205Phase 3Results posted
- Efficacy and Safety of Acetaminophen, Aspirin and Caffeine With Sumatriptan in the Acute Treatment of MigraineCompletedNCT01248468Phase 4Results posted
- Migraine Survey in Gulf RegionTerminatedNCT06237062
- Real-world Impact of Erenumab on Sick-leaves, Health Care Resource Use and Comorbidities.CompletedNCT05375097
- Healthcare Costs and Resource Utilization in Aimovig Migraine Patients: a Retrospective Study Using United States Claims DataCompletedNCT05177406
- Study of Quality of Life in Subjects With Chronic or High-frequency Episodic Migraine and Associated Comorbidities Treated With ErenumabWithdrawnNCT04114630Phase 3
- A Functional MRI Study on Erenumab Treatment Effects in Episodic Migraine PatientsCompletedNCT03977649Phase 4
- A Randomized,Double Blind, Placebo Controlled Study to Assess Efficacy,Safety and Tolerability of BGG492 in Migraine PreventionWithdrawnNCT01617941Phase 2
- Relative Bioavailability Study of Nadolol (1 x 80 mg) Tablets Under Fasting ConditionsCompletedNCT00960245Phase 1
- Efficacy and Safety of BGG492 in the Treatment of MigraineCompletedNCT00892203Phase 2